We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
- Authors
Yang, Xiaofei; Dai, Haiping; Kang, Liqing; Qu, Changju; Li, Zheng; Yin, Jia; Qiu, Huiying; Fu, Chengcheng; Han, Yue; Jin, Zhengming; Ma, Xiao; Zhu, Xiamin; Yu, Lei; Wu, Depei; Tang, Xiaowen
- Abstract
Patients with relapsing B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis, with a median survival of less than 6 months.[1] The treatment of relapsed B-ALL following allo-HSCT is challenging, and there is no standard approach available. Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapse/refractory B-cell malignancies. CAR-expressing T cells used in our study were produced from five patients' original transplant donors and the other 10 recipients themselves, respectively.
- Subjects
HEMATOPOIETIC stem cell transplantation; T cells; GRAFT versus host disease
- Publication
Hematological Oncology, 2019, Vol 37, Issue 5, p655
- ISSN
0278-0232
- Publication type
letter
- DOI
10.1002/hon.2682